View source for Phosphofructokinase 1

{{Short description|Class of enzymes}}
{{infobox enzyme
| Name       = 6-phosphofructokinase
| EC_number  = 2.7.1.11
| CAS_number = 9001-80-3
| GO_code    = 0003872
| image      = Phosphofructokinase 6PFK wpmp.png
| width      =
| caption    =  
}}
{{Infobox protein family
| Symbol = PFK
| Name = Phosphofructokinase
| image =
| width = 
| caption = Bacterial Phosphofructokinase: 3rd glycolysis enzyme (smaller than in Eukaryotes). In yellow=sugars; in red=ATP-ADP; starred=regulatory sites.<ref name="pmid6115424" />
| Pfam = PF00365
| Pfam_clan = CL0240
| InterPro = IPR000023
| SMART = 
| PROSITE = PDOC00336
| SCOP = 5pfk
| TCDB = 
| OPM family = 
| OPM protein = 
| PDB = {{PDB2|1kzh}}, {{PDB2|1mto}}, {{PDB2|1pfk}}, {{PDB2|1zxx}}, {{PDB2|2f48}}, {{PDB2|2pfk}}, {{PDB2|3pfk}}, {{PDB2|4pfk}}, {{PDB2|6pfk}}
}}

'''Phosphofructokinase-1''' ('''PFK-1''') is one of the most important regulatory [[enzymes]] ({{EC number|2.7.1.11}}) of [[glycolysis]]. It is an [[allosteric enzyme]] made of 4 subunits and controlled by many [[Enzyme activator|activators]] and [[Enzyme inhibitor|inhibitor]]s. PFK-1 catalyzes the important "committed" step of glycolysis, the conversion of [[fructose 6-phosphate]] and [[Adenosine triphosphate|ATP]] to fructose 1,6-bisphosphate and [[Adenosine diphosphate|ADP]]. Glycolysis is the foundation for respiration, both anaerobic and aerobic.  Because phosphofructokinase (PFK) catalyzes the ATP-dependent phosphorylation to convert fructose-6-phosphate into fructose 1,6-bisphosphate and ADP, it is one of the key regulatory steps of glycolysis.<ref>{{Cite journal |last1=Walker |first1=L.R. |last2=Simcock |first2=D.C. |last3=Pedley |first3=K.C. |last4=Simpson |first4=H.V. |author-link4=Heather Simpson (academic) |last5=Brown |first5=S. |date=April 2012 |title=The kinetics and regulation of phosphofructokinase from Teladorsagia circumcincta |url=https://doi.org/10.1016/j.exppara.2012.02.011 |journal=Experimental Parasitology |volume=130 |issue=4 |pages=348–353 |doi=10.1016/j.exppara.2012.02.011 |pmid=22402411 |issn=0014-4894|url-access=subscription }}</ref>  PFK is able to regulate glycolysis through allosteric inhibition, and in this way, the cell can increase or decrease the rate of glycolysis in response to the cell's energy requirements.  For example, a high ratio of ATP to ADP will inhibit PFK and glycolysis. The key difference between the regulation of PFK in eukaryotes and prokaryotes is that in eukaryotes PFK is activated by fructose 2,6-bisphosphate.  The purpose of fructose 2,6-bisphosphate is to supersede ATP inhibition, thus allowing eukaryotes to have greater sensitivity to regulation by hormones like glucagon and insulin.<ref name="Usenik" />
{{Enzymatic Reaction
|forward_enzyme=Phosphofructokinase 1
|reverse_enzyme=[[Fructose 1,6-bisphosphatase|Fructose bisphosphatase]]
|substrate=β-<small>D</small>-[[fructose 6-phosphate]]
|product=β-<small>D</small>-[[fructose 1,6-bisphosphate]]
|reaction_direction_(forward/reversible/reverse)=reversible
|minor_forward_substrate(s)=[[adenosine triphosphate|ATP]]
|minor_forward_product(s)=[[Adenosine diphosphate|ADP]]
|minor_reverse_substrate(s)=H<sub>2</sub>O
|minor_reverse_product(s)=P<sub>i</sub>
|substrate_image=beta-D-fructose-6-phosphate_wpmp.png
|product_image=beta-D-fructose-1,6-bisphosphate_wpmp.png
}}

== Structure ==
Mammalian PFK1 is a 340kd<ref name="Stryer"/> tetramer composed of different combinations of three types of subunits: [[muscle]] (M), [[liver]] (L), and [[platelet]] (P). The composition of the PFK1 [[tetramer]] differs according to the tissue type it is present in. For example, mature muscle expresses only the M [[isozyme]], therefore, the muscle PFK1 is composed solely of homotetramers of M4. The liver and kidneys express predominantly the L isoform. In [[erythrocytes]], both M and L subunits randomly tetramerize to form M4, L4 and the three hybrid forms of the enzyme (ML3, M2L2, M3L). As a result, the kinetic and regulatory properties of the various isoenzymes pools are dependent on subunit composition. Tissue-specific changes in PFK activity and isoenzymic content contribute significantly to the diversities of [[glycolysis|glycolytic]] and [[gluconeogenesis|gluconeogenic]] rates which have been observed for different tissues.<ref name="Dunaway"/>

PFK1 is an allosteric enzyme and has a structure similar to that of [[hemoglobin]] in so far as it is a dimer of a dimer.<ref name="pmid6115424">{{PDB|4pfk}}; {{cite journal | vauthors = Evans PR, Farrants GW, Hudson PJ | title = Phosphofructokinase: structure and control | journal = Philosophical Transactions of the Royal Society B | volume = 293 | issue = 1063 | pages = 53–62 |date=June 1981 | pmid = 6115424 | doi = 10.1098/rstb.1981.0059 | doi-access = free | bibcode = 1981RSPTB.293...53E }}
*{{cite web |title=The Glycolytic Enzymes |website=Protein Data Bank |url=http://www.pdb.org/pdb/static.do?p=education_discussion/molecule_of_the_month/pdb50_4.html |archive-url=https://web.archive.org/web/20101212000347/http://www.pdb.org/pdb/static.do?p=education_discussion/molecule_of_the_month/pdb50_4.html |archive-date=2010-12-12}}</ref> One half of each dimer contains the ATP binding site whereas the other half the substrate (fructose-6-phosphate or (F6P)) binding site as well as a separate allosteric binding site.<ref name="Shirakihara"/>

Each  subunit of the tetramer is 319 amino acids and consists of two domains: one that binds the substrate ATP, and the other that binds fructose-6-phosphate. Each domain is a [[beta barrel]], and has a cylindrical beta sheet surrounded by alpha helices.

On the opposite side of the each subunit from each active site is the allosteric site, at the interface between subunits in the dimer. ATP and AMP compete for this site. The N-terminal domain has a catalytic role binding the ATP, and the C-terminal has a regulatory role <ref name="Banaszak"/>

== Mechanism ==
PFK1 is an allosteric enzyme whose activity can be described using the [[MWC model|symmetry model]] of allosterism<ref name="Peskov"/> whereby there is a concerted transition from an enzymatically inactive T-state to the active R-state. F6P binds with a high affinity to the R state but not the T state enzyme. For every molecule of F6P that binds to PFK1, the enzyme progressively shifts from T state to the R state. Thus a graph plotting PFK1 activity against increasing F6P concentrations would adopt the [[sigmoid function|sigmoidal]] curve shape traditionally associated with allosteric enzymes.

PFK1 belongs to the family of [[phosphotransferases]] and it catalyzes the transfer of γ-phosphate from ATP to fructose-6-phosphate. The PFK1 [[active site]] comprises both the ATP-Mg2+ and the F6P binding sites. Some proposed residues involved with substrate binding in ''E. coli'' PFK1 include [[Aspartic Acid|Asp127]] and [[Arginine|Arg171]].<ref name="Hellinga"/> In [[Bacillus stearothermophilus|B. stearothermophilus]] PFK1, the positively charged side chain of Arg162 residue forms a hydrogen-bonded salt bridge with the negatively charged phosphate group of F6P, an interaction which stabilizes the R state relative to the T state and is partly responsible for the [[allosteric regulation|homotropic effect]] of F6P binding. In the T state, enzyme conformation shifts slightly such that the space previously taken up by the Arg162 is replaced with [[glutamic acid|Glu161]]. This swap in positions between adjacent amino acid residues inhibits the ability of F6P to bind the enzyme.

Allosteric activators such as [[Adenosine monophosphate|AMP]] and [[Adenosine diphosphate|ADP]] bind to the allosteric site as to facilitate the formation of the R state by inducing structural changes in the enzyme. Similarly, inhibitors such as ATP and [[Phosphoenolpyruvic acid|PEP]] bind to the same allosteric site and facilitate the formation of the T state, thereby inhibiting enzyme activity.

The hydroxyl oxygen of carbon 1 does a nucleophilic attack on the beta phosphate of ATP.  These electrons are pushed to the anhydride oxygen between the beta and gamma phosphates of ATP.<ref name="Phong"/><ref name="Papagianni"/>

[[File:AbhinavBiochemMechanism.JPG|thumb|Mechanism of phosphofructokinase 1]]

== Regulation ==
PFK1 is the most important control site in the mammalian glycolytic pathway. This step is subject to extensive regulation since it is not only highly [[exergonic]] under [[physiological condition]]s, but also because it is a committed step – the first irreversible reaction unique to the glycolytic pathway. This leads to a precise control of glucose and the other [[monosaccharide]]s [[galactose]] and [[fructose]] going down the glycolytic pathway. Before this enzyme's reaction, [[glucose-6-phosphate]] can potentially travel down the [[pentose phosphate pathway]], or be converted to glucose-1-phosphate for [[glycogenesis]].

PFK1 is [[allosterically]] inhibited by high levels of [[Adenosine triphosphate|ATP]] but AMP reverses the inhibitory action of ATP. Therefore, the activity of the enzyme increases when the cellular ATP/AMP ratio is lowered. Glycolysis is thus stimulated when energy charge falls. PFK1 has two sites with different affinities for ATP which is both a [[Substrate (biochemistry)|substrate]] and an inhibitor.<ref name="Stryer"/>

PFK1 is also inhibited by low pH levels which augment the inhibitory effect of ATP. The pH falls when muscle is functioning [[Lactic acid fermentation|anaerobically]] and producing excessive quantities of [[lactic acid]] (although lactic acid is not itself the cause of the decrease in pH<ref>{{Cite journal|title = Applying physicochemical principles to skeletal muscle acid-base status|url = http://ajpregu.physiology.org/content/289/3/R891|journal = American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|date = 2005-09-01|issn = 0363-6119|pmid = 16105823|pages = R891–R894|volume = 289|issue = 3|doi = 10.1152/ajpregu.00225.2005|language = en|first1 = Michael I.|last1 = Lindinger|first2 = John M.|last2 = Kowalchuk|first3 = George J. F.|last3 = Heigenhauser|url-access = subscription}}</ref>). This inhibitory effect serves to protect the muscle from damage that would result from the accumulation of too much acid.<ref name="Stryer"/>

Finally, PFK1 is allosterically inhibited by [[Phosphoenolpyruvic acid|PEP]], citrate, and ATP.  Phosphoenolpyruvic acid is a product further downstream the [[glycolysis|glycolytic]] pathway. Although citrate does build up when the Krebs Cycle enzymes approach their maximum velocity, it is questionable whether citrate accumulates to a sufficient concentration to inhibit PFK-1 under normal physiological conditions{{Citation needed|reason=This claim needs a reliable source|date=November 2013}}. ATP concentration build up indicates an excess of energy and does have an allosteric modulation site on PFK1 where it decreases the affinity of PFK1 for its substrate.

PFK1 is [[allosterically]] activated by a high concentration of [[Adenosine monophosphate|AMP]], but the most potent activator is [[fructose 2,6-bisphosphate]], which is also produced from fructose-6-phosphate by [[PFK2]]. Hence, an abundance of F6P results in a higher concentration of [[fructose 2,6-bisphosphate]] (F-2,6-BP). The binding of F-2,6-BP increases the affinity of PFK1 for F6P and diminishes the inhibitory effect of ATP. This is an example of feedforward stimulation as glycolysis is accelerated when glucose is abundant.<ref name="Stryer"/>

PFK activity is reduced through repression of synthesis by [[glucagon]]. Glucagon activates [[protein kinase A]] which, in turn, shuts off the kinase activity of [[PFK2]]. This reverses any synthesis of F-2,6-BP from F6P and thus de-activates PFK1.

The precise regulation of PFK1 prevents [[glycolysis]] and [[gluconeogenesis]] from occurring simultaneously. However, there is [[substrate cycling]] between F6P and F-1,6-BP. [[Fructose-1,6-bisphosphatase]] (FBPase) catalyzes the hydrolysis of F-1,6-BP back to F6P, the reverse reaction catalyzed by PFK1. There is a small amount of FBPase activity during glycolysis and some PFK1 activity during gluconeogenesis. This cycle allows for the amplification of metabolic signals as well as the generation of heat by ATP hydrolysis.

Serotonin (5-HT) increases PFK by binding to the 5-HT(2A) receptor, causing the tyrosine residue of PFK to be phosphorylated via phospholipase C. This in turn redistributes PFK within the skeletal muscle cells. Because PFK regulates glycolytic flux, serotonin plays a regulatory role in glycolysis <ref name="Coelho"/>

==Genes==
There are three phosphofructokinase genes in humans:
* [[PFKL]] – [[liver]]
* [[PFKM]] – [[muscle]]
* [[PFKP]] – [[platelet]]

==Clinical significance ==
A genetic mutation in the [[PFKM]] gene results in [[Phosphofructokinase deficiency|Tarui's disease]], which is a glycogen storage disease where the ability of certain cell types to utilize [[carbohydrates]] as a source of energy is impaired.<ref name="Nakajima"/>

Tarui disease is a glycogen storage disease with symptoms including muscle weakness (myopathy) and exercise induced cramping and spasms, myoglobinuria  (presence of myoglobin in urine, indicating muscle destruction) and compensated hemolysis. ATP is a natural allosteric inhibitor of PFK, in order to prevent unnecessary production of ATP through glycolysis. However, a mutation in Asp(543)Ala can result in ATP having a stronger inhibitory effect (due to increased binding to PFK's inhibitory allosteric binding site).<ref name="Bruser" /><ref name="pmid22995305">{{cite journal | vauthors = Brüser A, Kirchberger J, Schöneberg T | title = Altered allosteric regulation of muscle 6-phosphofructokinase causes Tarui disease | journal = Biochem. Biophys. Res. Commun. | volume = 427 | issue = 1 | pages = 133–7 |date=October 2012 | pmid = 22995305 | doi = 10.1016/j.bbrc.2012.09.024 }}</ref>

Phosphofructokinase mutation and cancer: In order for cancer cells to meet their energy requirements due to their rapid cell growth and division, they survive more effectively when they have a hyperactive phosphofructokinase 1 enzyme.<ref name="Gomez" /><ref name="Vaz" />  When cancer cells grow and divide quickly, they initially do not have as much blood supply, and can thus have hypoxia (oxygen deprivation), and this triggers [[O-GlcNAc]]ylation at serine 529 of PFK. This modification inhibits PFK1 activity and supports cancer proliferation, in contrast with the view that high PFK1 activity is necessary for cancer. This may be due to redirecting glucose flux towards the pentose phosphate pathway to generate NADPH to detoxify reactive oxygen species.<ref name="Yi" />

Herpes simplex type 1 and phosphofructokinase: Some viruses, including HIV, HCMV and Mayaro affect cellular metabolic pathways such as glycolysis by a MOI-dependent increase in the activity of PFK. The mechanism that Herpes increases PFK activity is by phosphorylating the enzyme at the serine residues. The HSV-1 induced glycolysis increases ATP content, which is critical for the virus's replication.<ref name="Abrantes"/>

==See also==
*[[PFK2]] (converts fructose 6-phosphate to fructose 2,6-bisphosphate through on site, or the opposite, on another site)
*[[PFP (enzyme)|PFP]] (reversibly interconverts fructose 6-phosphate and fructose 1,6-bisphosphate using inorganic [[pyrophosphate]] rather than ATP)
*[[fructose 1,6-bisphosphatase|Fructose bisphosphatase]] (hydrolyses fructose 1,6-bisphosphate to fructose 6-phosphate)

== References ==
{{reflist|35em|refs=

<ref name="Stryer">{{cite book | vauthors = Stryer L, Berg JM, Tymoczko JL  | title = Biochemistry | edition = Sixth | publisher = W.H. Freeman | location = San Francisco | year = 2007 | isbn = 978-0-7167-8724-2  }}</ref>

<ref name="Dunaway">{{cite journal | vauthors = Dunaway GA, Kasten TP, Sebo T, Trapp R | title = Analysis of the phosphofructokinase subunits and isoenzymes in human tissues | journal = Biochem. J. | volume = 251 | issue = 3 | pages = 677–83 |date=May 1988 | pmid = 2970843 | pmc = 1149058| doi =  10.1042/bj2510677}}</ref>

<ref name="Shirakihara">{{cite journal | vauthors = Shirakihara Y, Evans PR | title = Crystal structure of the complex of phosphofructokinase from Escherichia coli with its reaction products | journal = J. Mol. Biol. | volume = 204 | issue = 4 | pages = 973–94 |date=December 1988 | pmid = 2975709 | doi = 10.1016/0022-2836(88)90056-3  }}</ref>

<ref name="Hellinga">{{cite journal | vauthors = Hellinga HW, Evans PR | title = Mutations in the active site of Escherichia coli phosphofructokinase | journal = Nature | volume = 327 | issue = 6121 | pages = 437–9 | year = 1987 | pmid = 2953977 | doi = 10.1038/327437a0  | s2cid = 4357039 }}</ref>

<ref name="Peskov">{{cite journal | vauthors = Peskov K, Goryanin I, Demin O | title = Kinetic model of phosphofructokinase-1 from Escherichia coli | journal = J Bioinform Comput Biol | volume = 6 | issue = 4 | pages = 843–67 |date=August 2008 | pmid = 18763746 | doi = 10.1142/S0219720008003643 }}</ref>

<ref name="Nakajima">{{cite journal | vauthors = Nakajima H, Raben N, Hamaguchi T, Yamasaki T | title = Phosphofructokinase deficiency; past, present and future | journal = Curr. Mol. Med. | volume = 2 | issue = 2 | pages = 197–212 |date=March 2002 | pmid = 11949936 | doi = 10.2174/1566524024605734 }}</ref><ref name="Bruser">{{cite journal | vauthors = Bruser A, KirchbergerJ, Schoneberg T | title = Altered allosteric regulation of muscle 6-phosphofructokinase causes Tarui disease | journal = Biochem Biophys Res Commun | volume = 427 | issue = 1 | pages = 133–7 |date=Oct 2012 | pmid = 22995305| doi = 10.1016/j.bbrc.2012.09.024 }}</ref>

<ref name="Coelho">{{cite journal | vauthors = Coelho WS, Sola-Penna M | title = Serotonin regulates 6-phosphofructo-1-kinase activity in a PLC-PKC-CaMK II- and Janus kinase-dependent signaling pathway | journal = Mol. Cell. Biochem. | volume = 372| issue = 1–2 | pages = 211–20 |date=Jan 2013 | pmid = 23010892| doi = 10.1007/s11010-012-1462-0 | s2cid = 14570273 }}</ref>

<ref name="Banaszak">{{cite journal | vauthors = Banaszak K, Mechin I, Obmolova G, Oldham M, Chang SH, Ruiz T, Radermacher M, Kopperschläger G, Rypniewski W | title = The crystal structures of eukaryotic phosphofructokinases from baker's yeast and rabbit skeletal muscle | journal = J Mol Biol | volume =  407| issue = 7 | pages = 284–97 |date=March 2011 | pmid = 21241708 | doi = 10.1016/j.jmb.2011.01.019 }}</ref>

<ref name="Yi">{{cite journal | vauthors = Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA, Peters EC, Driggers EM, Hsieh-Wilson LC | title = Phosphofructokinase 1 glycosylation regulates cell growth and metabolism | journal = Science  | volume = 337| issue = 6097 | pages = 975–80 |date=Aug 2012 | pmid = 22923583 | pmc = 3534962| doi = 10.1126/science.1222278 | bibcode = 2012Sci...337..975Y }}</ref>

<ref name="Abrantes">{{cite journal | vauthors = Abrantes JL, Alves CM, Costa J, Almeida FC, Sola-Penna M, Fontes CF, Souza TM | title = Herpes simplex type 1 activates glycolysis through engagement of the enzyme 6-phosphofructo-1-kinase (PFK-1)| journal = Biochim Biophys Acta | volume = 1822| issue = 8| pages = 1198–206 |date=Aug 2012 | pmid = 22542512 | doi = 10.1016/j.bbadis.2012.04.011 | doi-access = free }}</ref>

<ref name="Phong">{{cite journal | vauthors = Phong WY, Lin W, Rao SP, Dick T, Alonso S, Pethe K | title = Characterization of Phosphofructokinase Activity in Mycobacterium tuberculosis Reveals That a Functional Glycolytic Carbon Flow Is Necessary to Limit the Accumulation of Toxic Metabolic Intermediates under Hypoxia | journal = PLOS ONE | volume = 8 | issue = 2 | pages = 1198–206 |date=Aug 2013| pmid = 23409118
| pmc = 3567006| doi = 10.1371/journal.pone.0056037 | editor1-last = Parish | editor1-first = Tanya | doi-access = free | bibcode = 2013PLoSO...856037P }}</ref><ref name="Gomez">{{cite journal | vauthors = Gomez LS, Zancan P, Marcondes MC, Ramos-Santos L, Meyer-Fernandes JR, Sola-Penna M, Da Silva D | title = Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase| journal = Biochimie | volume = 95| issue = 6| pages = 1336–43|date=Feb 2013| pmid = 23454376| doi = 10.1016/j.biochi.2013.02.013 | doi-access = free}}</ref>

<ref name="Vaz">{{cite journal | vauthors = Vaz CV, Alves MG, Marques R, Moreira PI, Oliveira PF, Maia CJ, Socorro S | title = Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile| journal = Int J Biochem Cell Biol | volume = 44 | issue = 11 | pages = 2077–84 |date=Feb 2013 | pmid = 22964025 | doi = 10.1016/j.biocel.2012.08.013  }}</ref>

<ref name="Papagianni">{{cite journal | vauthors = Papagianni M, Avramidis N | title = Engineering the central pathways in Lactococcus lactis: functional expression of the phosphofructokinase (pfk) and alternative oxidase (aox1) genes from Aspergillus niger in Lactococcus lactis facilitates improved carbon conversion rates under oxidizing conditions| journal = Enzyme and Microbial Technology | volume = 51| issue = 113 | pages = 125–30 |date=May 2012 | pmid = 22759530 | doi = 10.1016/j.enzmictec.2012.04.007 }}</ref>

<ref name="Usenik">{{cite journal | vauthors = Usenik A, Legiša M | title = Evolution of allosteric citrate binding sites on 6-phosphofructo-1-kinase| journal = PLOS ONE | volume = 5| issue = 11|pages = 677–683|date=Nov 2010 | pmid = 21124851 | pmc = 2990764 | doi = 10.1371/journal.pone.0015447 | editor1-last = Kobe | editor1-first = Bostjan | doi-access = free| bibcode = 2010PLoSO...515447U}}</ref>

}}

==External links==
* {{MeshName|Phosphofructokinase-1}}
* [http://www.proteopedia.org/wiki/index.php/Phosphofructokinase_%28PFK%29 Proteopedia.org Phosphofructokinase]
* {{PDBe-KB2|P08237| ATP-dependent 6-phosphofructokinase, muscle type}}
* {{PDBe-KB2|Q01813| ATP-dependent 6-phosphofructokinase, platelet type}}

{{glycolysis}}
{{Glycolysis enzymes}}
{{Kinases}}
{{Enzymes}}
{{Portal bar|Biology|border=no}}

[[Category:EC 2.7.1]]
[[Category:Glycolysis]]